Japan Pharmaceutical Manufacturing Market size was US$ 31.74 billion in 2022 and is projected to reach a market size of US$ 53.90 billion by 2031, growing at a CAGR of 6.06% during the forecast period from 2023 to 2031.
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/japan-pharmaceutical-manufacturing-market
The pharmaceutical manufacturing market in Japan is expanding and rapidly changing. Japan will continue to be a leader in pharmaceutical innovation for years due to a potent combination of a commitment to precision engrained in its culture, an aging population, and forward-thinking regulations. The rise in the elderly population, the prevalence of chronic diseases, and increased R&D (research and development) expenditures in Japan are contributing to the market’s expansion.
The market is expanding due to the increase in infections and chronic diseases like cancer, diabetes, hypertension, cancer, cardiovascular diseases, and other conditions. The GLOBOCAN research projects that there will be 1,110,549 cancer cases in Japan by 2030 and 1,128,057 by 2040. Thus, the anticipated rise in the number of cancer patients will increase demand for potent medications and propel the market’s expansion.
The country’s rising senior population is a factor in the market’s expansion. According to UNPF’s 2022 statistics, 59% of Japan’s total population will be between the ages of 15 and 64 in 2022. In 2022, 29% of the population will be 65 years of age or older, according to the same source. As a result, the aging population is more likely to suffer chronic illnesses such as cancer, neurological disorders, and cardiovascular diseases, which is likely to increase demand for effective therapies and accelerate the market’s growth.
The nation is growing as a result of rising investments and advancements in the pharmaceutical industry. This is expected to fuel market expansion. For instance, in March 2023, Takeda started the largest-ever investment in Japanese manufacturing capacity. The company, situated in Osaka, Japan, will construct a new manufacturing facility for plasma-derived medicines, which will enhance the output five times more. Additionally, in May 2022, ExoCoBio Inc. obtained a Japanese patent asserting that exosomes produced from stem cells are a potent treatment for dermatitis.
Generic Drugs Captured for About 60% of Market Revenue Share
Generic prescription drugs dominated the market in Japan, which is indicative of the priorities and budgetary constraints of the global healthcare industry. This market sector generates more than 60% of total revenue and has expanded quickly due to a variety of interrelated factors.
The request of Full Report Here- https://www.astuteanalytica.com/industry-report/japan-pharmaceutical-manufacturing-market
The staggering number of patent expirations between 2020 and 2025 is likely to fuel the generic pharmaceutical market, contributing to the segment’s excellent CAGR of 7.34%. Now that the World Health Organization (WHO) has stressed the importance of generic medications for realizing the goal of universal health coverage, the campaign for generic drugs is likely to gain momentum.
Tablet Formulation Capture About 32% of Market Revenue Share
The most common pharmaceutical formulation is tablets, which hold a strong 31.94% market share of the pharmaceutical production business. This supremacy is due to consumer choices and production advantages, and it comes with an anticipated CAGR of 7.37%.
Tablets provide simplicity of administration, portability, and precise dose from the consumer’s perspective. The demand for tablet formulations is directly correlated with the development of lifestyle disorders like diabetes and hypertension. Tablets have a number of benefits in terms of manufacturing. They are more stable for a longer period of time, ship for less money, and scale more easily.
Pain Management Capture About 33% of Market Revenue Share
Pain management appears as the main therapeutic area in Japan’s pharmaceutical manufacturing sector, holding a 33.10% market share. In Japan alone, 34% of individuals experience pain, and a startling 10% of people receive a chronic pain diagnosis for the first time each year. The aging of Japan’s population is the cause of this expansion.
As a result of realizing this demand, pharmaceutical companies have expanded their R&D spending on pain management. The Japanese pharmaceutical manufacturing market is flooded with products for conditions like neuropathic pain, including over-the-counter medicines, prescription medications, and even specialty medications.
Competitive Insights
The competitive environment of the Japan pharmaceutical market includes the leading companies. The pharmaceutical industry in Japan is extremely competitive and includes several notable companies. In terms of market share, a small number of important companies dominate the industry under investigation. A select group of significant players are aggressively investing in other companies and forming joint ventures with them in an effort to improve their market positions across the country.
List of Prominent Players are:
- Abbott Laboratories
- AbbVie Inc.
- ACADIA Pharma
- Aenova Group
- Amgen
- Astellas Pharma Inc.
- AstraZeneca
- Bayer AG
- Biogen
- Boehringer Ingelheim International GmbH
- Chugai Pharmaceutical Co., Ltd
- Daiichi Sankyo
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Novo Nordisk
- Pfizer, Inc.
- Sanofi SA
- Takeda
- Other Prominent Players
Segmentation Outline
The Japan pharmaceutical manufacturing market segmentation focuses on Drug Type, Formulation, Route of Administration, Therapeutic Application, Manufacturing Facility, and Distribution Channel.
By Drug Type
- Branded Prescription Drugs
- Generic Prescription Drugs
- Over-the-counter drugs (OTC)
By Formulation
- Tablets
- Capsules
- Injectables
- Sprays
- Suspensions
- Powder
- Other Formulations
By Route of Administration
- Oral Medicine
- Topical Medicine
- Parenteral Medicine
- Inhalations
- Other Routes of Administration
By Therapeutic Application
- Cardiovascular Disease
- Pain
- Disease
- Cancer
- Respiratory Diseases
- Neurological Diseases
- Orthopedics
- Other Therapeutic Application
By Manufacturing Facility
- In-House Facility
- Outsourced facility
By Distribution Channel
- Retail Channel
- Non-retail
- Online Channel
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/japan-pharmaceutical-manufacturing-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com